Second Person Cured of HIV Is Still Free of Active Virus Two Years On (cnn.com)39
An anonymous reader quotes a report from CNN:The second person ever to be cured of HIV is still free of active virus more than two years on, a study published by medical journal The Lancet HIV revealed on Tuesday. Two and a half years ago, Adam Castillejo -- previously identified as the "London patient" -- finished HIV antiretroviral therapy. He underwent a stem cell transplant to treat lymphoma and his donor carried a mutation known as CCR5-delta 32, which made him resistant to HIV. Researchers said that in treating his lymphoma, they believe Castillejo, now 40, was cured of HIV.
"Our findings show that the success of stem cell transplantation as a cure for HIV, first reported nine years ago in the Berlin patient, can be replicated," said Ravindra Gupta, lead author of the study and a professor in University of Cambridge's clinical microbiology department. Unlike the Berlin patient -- identified later as Timothy Ray Brown -- Castillejo underwent only one stem-cell transplantation instead of two and did not have radiotherapy to his entire body as part of his treatment. Castillejo represents a step toward a less intensive treatment approach, the authors said. Still, given the invasive nature of the experimental treatment, the authors caution its widespread use.
"Our findings show that the success of stem cell transplantation as a cure for HIV, first reported nine years ago in the Berlin patient, can be replicated," said Ravindra Gupta, lead author of the study and a professor in University of Cambridge's clinical microbiology department. Unlike the Berlin patient -- identified later as Timothy Ray Brown -- Castillejo underwent only one stem-cell transplantation instead of two and did not have radiotherapy to his entire body as part of his treatment. Castillejo represents a step toward a less intensive treatment approach, the authors said. Still, given the invasive nature of the experimental treatment, the authors caution its widespread use.